IP
CDTX

Isthmus Partners’s Cidara Therapeutics CDTX Stock Holding History

Isthmus Partners’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-100
Closed -$4K – 170
2021
Q2 		$4K Buy
+100
New +$4.23K ﹤0.01% 253
2018
Q4 		– Sell
-100
Closed -$9K – 159
2018
Q3 		$9K Hold
100
– – ﹤0.01% 245
2018
Q2 		$10K Hold
100
– – ﹤0.01% 233
2018
Q1 		$8K Buy
+100
New +$13.7K ﹤0.01% 233

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Isthmus Partners's CDTX Position: Q3 2021 in Review

Isthmus Partners sold out of Cidara Therapeutics (CDTX) in Q3 2021, closing a stake of 100 shares — an estimated $4K sold.

Isthmus Partners first reported a position in CDTX in Q1 2018 and held it in 4 quarters. The position peaked at $10K in Q2 2018. 50 funds tracked by Wall St. Rank hold CDTX as of Q3 2021.

  • Isthmus Partners reported no remaining Cidara Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Isthmus Partners sold 100 Cidara Therapeutics shares in Q3 2021, an estimated $4K.
  • Isthmus Partners first reported a position in Cidara Therapeutics in Q1 2018 and held it in 4 quarters.
  • Isthmus Partners's Cidara Therapeutics position peaked at $10K in Q2 2018.
  • 50 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2021.

Based on Isthmus Partners's 13F filing for Q3 2021, filed 10 Nov 2021.